Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
mercredi, septembre 23
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Viridian Therapeutics Inc
VRDN
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$22.12
0.54
2.5%
À la clôture: Sep 21, 5:00 PM EST
$22.19
0.61
2.83%
Pré-ouverture: 4:55 AM EST
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Viridian Therapeutics Financials
Viridian Therapeutics (VRDN) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Viridian Therapeutics Q2 EPS $(1.05) Misses $(1.02) Estimate, Sales $233.000K Beat $22.308K Estimate
Viridian Therapeutics (NASDAQ:VRDN) reported quarterly losses of $(1.05) per share which missed the analyst consensus estimate of $(1.02) by 2.94 percent. This is a 5 percent decrease over losses of $(1.00) per share
Benzinga Newsdesk
Stock Market Today: Nasdaq, Dow S&P 500 Futures Jump As Trump Admin Says US, Iran Will 'Stand Down' For Now— Verizon, HP, Universe Pharmaceuticals In Focus (UPDATED)
U.S. stock futures rose on Monday, as the Dow Jones, Nasdaq 100, and S&P 500 indices rose, following Friday's mixed close.
Rishabh Mishra
Concentrix, AeroVironment And 3 Stocks To Watch Heading Into Monday
U.S. stock futures up, watch Concentrix Corp, Lantheus Holdings, AeroVironment, Viridian Therapeutics, Universe Pharmaceuticals for earnings and news.
Avi Kapoor
PRO
Viridian Therapeutics Q1 EPS $(0.90) Beats $(1.05) Estimate, Sales $141.000K Beat $27.500K Estimate
Viridian Therapeutics (NASDAQ:VRDN) reported quarterly losses of $(0.90) per share which beat the analyst consensus estimate of $(1.05) by 14.29 percent. This is a 3.45 percent decrease over losses of $(0.87) per share
Benzinga Newsdesk
Earnings Breakdown: Viridian Therapeutics Q4
Benzinga Insights
PRO
Viridian Therapeutics Q4 EPS $(1.08) Misses $(0.93) Estimate, Sales $132.000K
Viridian Therapeutics (NASDAQ:VRDN) reported quarterly losses of $(1.08) per share which missed the analyst consensus estimate of $(0.93) by 16.76 percent. This is a 33.33 percent decrease over losses of $(0.81) per
Benzinga Newsdesk
Privacy Manager